Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Oyster Point Pharma, Inc. OYST
$11.17
На 18:02, 12 мая 2023
+34.29%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
0.00000000
-
week52high
13.45
-
week52low
3.46
-
Revenue
24539000
-
P/E TTM
-2
-
Beta
0.00000000
-
EPS
0.00000000
-
Last Dividend
0.00000000
-
Next Earnings Date
24 февр 2023 г. в 01:26
Описание компании
Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Chardan Capital | Buy | 11 авг 2022 г. | |
| HC Wainwright & Co. | Buy | 18 июл 2022 г. | |
| JP Morgan | Neutral | Overweight | 09 ноя 2021 г. |
| Piper Jaffray | Overweight | 25 ноя 2019 г. | |
| JP Morgan | Overweight | 25 ноя 2019 г. | |
| Piper Sandler | Neutral | Overweight | 08 ноя 2022 г. |
| Chardan Capital | Neutral | Buy | 08 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| New Enterprise Associates 14, L.P. | D | 0 | 5925287 | 03 янв 2023 г. |
| Behbahani Ali | D | 0 | 5199 | 03 янв 2023 г. |
| Behbahani Ali | D | 0 | 5199 | 03 янв 2023 г. |
| Behbahani Ali | D | 3573 | 10066 | 03 янв 2023 г. |
| WEISNER AIMEE S | D | 0 | 5199 | 03 янв 2023 г. |
| WEISNER AIMEE S | D | 0 | 5199 | 03 янв 2023 г. |
| WEISNER AIMEE S | D | 3573 | 33191 | 03 янв 2023 г. |
| Santel Donald J | D | 0 | 5359 | 03 янв 2023 г. |
| Santel Donald J | D | 0 | 5359 | 03 янв 2023 г. |
| Santel Donald J | D | 8198 | 5489 | 03 янв 2023 г. |
Новостная лента
OYSTER PT PHARM (OYST) Reports Q3 Loss, Lags Revenue Estimates
Zacks Investment Research
10 ноя 2022 г. в 18:48
OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of 9.87% and 24.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Viatris (VTRS) Is Buying Oyster Point (OYST)
Pulse2
07 ноя 2022 г. в 20:53
Viatris (VTRS) announced it is buying Oyster Point Pharma (OYST). This is why.
Oyster Point Pharma To Report Third Quarter 2022 Financial Results On November 10, 2022
GlobeNewsWire
02 ноя 2022 г. в 16:02
Conference Call and Webcast Scheduled for November 10, 2022, 4:30 p.m. ET Conference Call and Webcast Scheduled for November 10, 2022, 4:30 p.m. ET
Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIII
GlobeNewsWire
27 сент 2022 г. в 08:00
Two Featured Presentations will Include a Post-Hoc Analysis of TYRVAYA® (varenicline solution) Nasal Spray and Tear Film Cytokine Research Two Featured Presentations will Include a Post-Hoc Analysis of TYRVAYA® (varenicline solution) Nasal Spray and Tear Film Cytokine Research
Oyster Point Pharma to Present Analyses at the Women in Ophthalmology Summer Symposium
GlobeNewsWire
25 авг 2022 г. в 08:00
PRINCETON, N.J., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced the presentation of analyses at the Women in Ophthalmology (WIO) Summer Symposium, which is taking place in Monterey, California from August 25-28, 2022.